Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
PaperCitations, authors & open-access status
Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 266 citations, 2012 year and bronze oa status.
266
Citations
2012
Year
bronze
OA Status